1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
P/B ratio for 180 Life Sciences Corp. (ATNF)
P/B ratio as of 2023: -12.05
According to 180 Life Sciences Corp.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -12.05. At the end of 2022 the company had a P/B ratio of 0.57.
P/B ratio history for 180 Life Sciences Corp. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -12.05 |
| 2022 | 0.57 |
| 2021 | 3.09 |
| 2020 | 1.61 |
| 2019 | 0.44 |
| 2018 | -1.93 |
| 2017 | 2.20 |